BCI Maker Epia Neuro Bets On ‘Intent-Driven’ Rehab For Stroke Patients With Implant, Glove
Epia Neuro is developing an implantable BCI that is paired with a motorized glove to help stroke survivors regain hand function. The device is designed for standard rehabilitation and long-term use at home.
Medtech Insight - April 6, 2026

Venture Funding Keeps A Steady Pace In Q1
At $7.94bn, the first quarter of 2026 fell only slightly below the $8.04bn in venture capital raised by biopharma companies in Q4 of 2025, which was the biggest quarter in years.
Scrip - April 6, 2026

Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno
Building a portfolio led by three first-in-class potential blockbuster products drove Neurocrine’s willingness to pay a premium to get Vykat XR, which may not face any imminent competition.
Scrip - April 6, 2026

US FDA Warning Letters - February-March 2026
Nine companies received US FDA warning letters in February and March 2026, including Avertix Medical, Exactech and Flextronics.
Medtech Insight - April 6, 2026

Philips Recalls Thousands Of X-Ray Systems Due To ‘Device Design’ Malfunction
The US FDA attributes a Philips recall of more than 20,000 fluoroscopy systems to device design. Philips says it is installing corrective measures to address the problem.
Medtech Insight - April 6, 2026

Amgen’s Subcutaneous Tepezza Scores In TED As More Convenient Version
The company announced topline results showing efficacy consistent with the I.V. version, with convenience likely to be a competitive factor versus Viridian’s elegrobart and veligrotug.
Scrip - April 6, 2026

Pipeline Watch: Thirteen Approvals And Eighteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026

CapVest Has ‘Ambitious Plans’ For Stada As It Completes Takeover
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
HBW Insight - April 6, 2026

Neurocrine Takes ‘Sensible Way Into Metabolic Disease’ With $2.9bn Soleno Buy
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026

Xbrane Delays Refiling Ranibizumab Biosimilar With US FDA To Late Spring
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026

Henlius Targets Phesgo With Next-Wave Biosimilar Strategy
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026

Thermo Fisher Accelerates Biosimilars Race With New Platform
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026

BioBytes: Evogene Bets On Autonomous Small-Molecule Discovery
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026

HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026

US FDA Foods Program Chief Outlines ‘Nimble And Adaptable’ Supplement Industry Regulation
“The industry has grown and changed tremendously in the last 30 plus years, yet the regulatory framework has largely stayed the same,” says FDA Deputy Commissioner Kyle Diamantas. “We'll be setting up the agency to lower costs and enabling regulated industries to increase access to automation.”
HBW Insight - April 6, 2026

‘Dietary Substance For Use By Man To Supplement The Diet’: Open Or Closed Door For Innovation?
The phrase “a dietary substance for use by man to supplement the diet by increasing the total dietary intake,” known as “Clause E” [21 USC 321 (ff)(E)], is prompting what will comparatively be countless words in comments to FDA about the future of NDIs for the US.
HBW Insight - April 6, 2026